Results 11 to 20 of about 1,937,987 (265)

Treatment of drug-induced immune thrombocytopenias

Haematologica, 2022
Several therapeutic agents can cause thrombocytopenia by either immune-mediated or non-immune-mediated mechanisms. Non-immune-mediated thrombocytopenia is due to direct toxicity of drug molecules to platelets or megakaryocytes.
Irene Marini, Gunalp Uzun, Kinan Jamal, Tamam Bakchoul   +3 more
doaj   +1 more source

The role of CD8+ T-cell clones in immune thrombocytopenia

Blood, 2023
Key Points • Patients with chronic ITP had clonal expansions of disease-associated TEMRA CD8+ T cells.• CD8+ T cells bind to platelets and cause their activation and apoptosis, defining an antibody-independent mechanism of platelet destruction.
A. Malik, Anwar A. Sayed, P. Han, M. M. Tan, E. Watt, Adela Constantinescu-Bercu, A. Cocker, A. Khoder, Rocel C. Saputil, E. Thorley, Ariam Teklemichael, Yunchuan Ding, A. Hart, Haiyu Zhang, W. Mitchell, N. Imami, J. Crawley, Isabelle I. Salles‐Crawley, J. Bussel, J. Zehnder, S. Adams, Bing M. Zhang, N. Cooper   +22 more
semanticscholar   +1 more source

Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.

New England Journal of Medicine, 2022
BACKGROUND Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fcγ receptor)-mediated ...
D. Kuter, M. Efraim, J. Mayer, M. Trněný, V. Mcdonald, R. Bird, Thomas Regenbogen, M. Garg, Z. Kaplan, N. Tzvetkov, P. Choi, A. G. Jansen, M. Kostal, R. Baker, J. Gumulec, Eun-Ju Lee, I. Cunningham, Isaac Goncalves, M. Warner, R. Boccia, T. Gernsheimer, W. Ghanima, O. Bandman, R. Burns, A. Neale, Dolca Thomas, P. Arora, Beiyao Zheng, N. Cooper   +28 more
semanticscholar   +1 more source

Comparison of Published Guidelines for the Diagnosis and the Management of Vaccine-Induced Immune Thrombotic Thrombocytopenia

Critical Care Explorations, 2021
OBJECTIVES:. The development of thrombocytopenia and thrombosis after the administration of the AstraZeneca and Johnson & Johnson/Janssen vaccines has been recently described.
Luca Zazzeron, MD, Rachel P. Rosovsky, MD, Edward A. Bittner, MD, PhD, Marvin G. Chang, MD, PhD   +3 more
doaj   +1 more source

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Blood, 2021
We report five cases of prothrombotic immune thrombocytopenia after exposure to the ChAdOx1 vaccine (AZD1222, Vaxzevria) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients presented 5 to 11 days after first vaccination.
A. Tiede, U. Sachs, A. Czwalinna, S. Werwitzke, Rolf Bikker, J. Krauss, F. Donnerstag, K. Weissenborn, Günter U. Höglinger, B. Maasoumy, H. Wedemeyer, A. Ganser   +11 more
semanticscholar   +1 more source

Reliability and validity of the Amharic version of immune thrombocytopenia life quality index tool for assessment of the health-related quality of life in Ethiopian patients of immune thrombocytopenia: Cross-sectional study

SAGE Open Medicine, 2023
Background: Platelet count and bleeding risk are frequently used in clinical assessments of the severity of immune thrombocytopenia. On the other hand, immune thrombocytopenia also influences patients’ health-related quality of life.
Dessale Abate Beyene, Eskinder Ayalew Sisay, Atalay Mulu Fentie, Amha Gebremedhin   +3 more
doaj   +1 more source

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

Annals of Hematology, 2022
Chronic primary immune thrombocytopenia (ITP) can today benefit from multiple therapeutic approaches with proven clinical efficacy, including rituximab, thrombopoietin receptor agonists (TPO-RA), and splenectomy.
N. Vianelli, G. Auteri, F. Buccisano, V. Carrai, E. Baldacci, C. Clissa, D. Bartoletti, G. Giuffrida, D. Magro, E. Rivolti, D. Esposito, G. Podda, F. Palandri   +12 more
semanticscholar   +1 more source

Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia

Blood Advances, 2022
Key Points • Classical complement pathway activation contributes to the pathophysiology and clinical heterogeneity of immune thrombocytopenia (ITP).• Sutimlimab rapidly and durably increased platelet count in patients with chronic ITP by selectively ...
C. Broome, A. Röth, D. Kuter, M. Scully, Roy E. Smith, Jennifer P. Wang, C. Reuter, W. Hobbs, A. Daak   +8 more
semanticscholar   +1 more source

Management of immune thrombocytopenia during COVID-19 pandemic

Russian journal of hematology and transfusiology, 2021
Introduction. The COVID-19 pandemic has challenged health professionals and patients suffering from haematological diseases with embarrassed diagnosis, treatment, surveillance, social distancing and other constraints.Aim — addressing therapy for immune ...
S. V. Semochkin, T. Mitina, T. Tolstykh
semanticscholar   +1 more source

Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT)

Journal of Thrombosis and Haemostasis, 2021
Cases of unusual thrombosis and thrombocytopenia after administration of the ChAdOx1 nCoV‐19 vaccine (AstraZeneca) have been reported. The term vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) was coined to reflect this new phenomenon.
J. Thaler, C. Ay, K. Gleixner, A. Hauswirth, Filippo Cacioppo, G. Jürgen, P. Quehenberger, I. Pabinger, P. Knöbl   +8 more
semanticscholar   +1 more source